Given these observations, a multimodal diagnostic approach combining cytology, molecular markers (e.g., MAML2 status), and imaging could be recommended for MEC cases in the SUMP and suspicious categories to optimize preoperative assessment and treatment planning. This evidence concerns the gene MAML2 and mucoepidermoid carcinoma.